Phase 2 N=9 Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight — 0.70 lbs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=360 Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Heart Failure
Primary: 96 Hour Change in NT-proBNP — -0.58; -0.61 log pg/ml — p=0.5688
Phase 2 N=20 Study of Leptin for the Treatment of Hypothalamic Amenorrhea
Amenorrhea
Primary: the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks…
N/A N=178 Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer
Lumbar Degenerative Disc Disease
Primary: Number of Subjects With Successful Radiographic Fusion — 90 Participants
N/A N=73 Safety and Effectiveness of the MED-EL Electric-Acoustic System
Hearing Loss
Primary: Improvement in Speech Perception in Noise With EAS When Compared to the Preoperative Hearing Aid Alone Condition. — 42.2 percentage of words correct (CUNY)
N/A N=18 Bone Tunnel Widening Following ACL Reconstruction
Anterior Cruciate Ligament Injury · Knee Injuries
Primary: Bone Tunnel Diameter — 14.4 mm
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
Phase 2 N=50 Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
Cardiac Arrest
Primary: Time to Shock Reversal — 55; 49 hours
N/A N=131 Comparative Outcomes Management With Electronic Data Technology (COMET) Study
Sleep Apnea, Obstructive
Primary: Nocturnal Mean Arterial Blood Pressure (NMAP) at 2 Months — 82.1; 84.3 mmHg — p=0.2067
Phase 2 N=55 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Donor Engraftment (Chimerism) — 34 Participants
Phase 2 N=16 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
Endocrine Disease · Adrenal Insufficiency · Congenital Adrenal Hyperplasia
Primary: Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia — 601.213 nmol/L
N/A N=16 Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults
Systemic Proinflammatory State
Primary: Vascular and Systemic Inflammation as Measured by Interleukin-6 (IL-6) Serum Levels — 1.70; 1.51; 1.65; 1.78 ng/mL
Phase 4 N=21 Pilot Study of Using Copeptin to Predict Response to Tolvaptan
Cardiovascular Diseases · Heart Diseases · Heart Failure
Primary: Urine Output — 6498; 5784 mL — p=0.853
N/A N=22 Treatment With Namenda in Women at Risk for Cognitive Decline
Dementia
Primary: Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2 — 20.41 percentage of target words recalled
Phase 3 N=711 Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Hyperlipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12 — 1.0; -55.6 percent change — p=<0.001